HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
44 hedge funds and large institutions have $15M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 9 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 43 → 44 (+1)
30% less capital invested
Capital invested by funds: $21.5M → $15M (-$6.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$5.59M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.36M |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$1.97M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.32M |
| 5 |
SCM
Sio Capital Management
New York
|
+$336K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.34M |
| 2 |
RA
Royce & Associates
New York
|
-$794K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$596K |
| 4 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$249K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$106K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TSS
51
Two Sigma Securities
New York
| – | -$18K | -62 | Closed |
|
52
UBS Group
Zurich,
Switzerland
| – | -$8.05K | -40 | -93% |
|
HTGM Hedge Fund Activity: Q3 2019 in Review
44 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q3 2019, worth a combined $15M — down 30% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new HTGM positions and 9 closed out — a net gain of 1 holder — while 13 added to existing stakes and 11 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $5.59M. The largest seller was Granahan Investment Management, exiting entirely with an estimated $1.34M sold.
- 44 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q3 2019, up from 43 in Q2 2019.
- Funds reported $15M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q3 2019, down 30% quarter-over-quarter.
- 10 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +1 holder.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q3 2019 was Nantahala Capital Management, an estimated $5.59M added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q3 2019 was Granahan Investment Management, an estimated $1.34M sold.
Based on aggregated 13F filings for Q3 2019.